Business Monitor International


Morocco Pharmaceuticals & Healthcare Report

Published 30 June 2014

  • 113 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Morocco Pharmaceuticals & Healthcare Report

BMI View: Despite the Moroccan government announcing a new economic policy prioritising the innovative biopharmaceutical industry as a strategic sector within the economy, unclear policy formation processes and underdeveloped institutions will continue to cloud the country's pharmaceutical investment outlook in the medium - to - long term. An unstable and inefficient regulatory environment works to create a tough operating environment for drugmakers - particularly challenging in a market also characterised by demand side issues such as low health insurance coverage and weak healthcare infrastructure.

Headline Expenditure Projections

  • Pharmaceuticals: MAD9.32bn (USD1.11bn) in 2013 to MAD9.58bn (USD1.15bn) in 2014; +2.8% in local currency terms and +3.1% in US dollar terms.

  • Healthcare: MAD57.96bn (USD6.90bn) in 2013 to MAD63.26bn (USD7.56bn) in 2014; +9.1% in local currency terms and +9.5% in US dollar terms. Forecast higher than in Q 214 due to upward revision of historical figures for pharmaceutical market.

Risk/Reward Rating

In our latest proprietary Pharmaceutical Risk/Reward Ratings (RRR), Morocco continues to be viewed as a moderately attractive pharmaceutical market in the Middle East and Africa (MEA) region, from a longer-term perspective. Morocco ranks 15 th in the region, out of the 30 countries assessed in our ratings matrix, with a score of 42.3 out of 100. The market's constraints include low per capita consumption and an underdeveloped reimbursement system, although such factors are to a degree offset by a relatively predictable operating environment.

Key Trends And Developments

June

More than 60mn medicines will be sold at reduced prices in Morocco from June 9, reports almaghribia.ma. The government lowered the prices of medicines belonging to 989 medical specialties by 20-80%. The government has focused particularly on decreasing the prices of medicines used in the treatment of various heart diseases, metabolic diseases and cancerous...

Table of Contents

BMI Industry View
7
SWOT
9
Political
11
Economic
12
Business Environment
13
Industry Forecast
14
Pharmaceutical Market Forecast
14
Table: Pharmaceutical Sales, Historical Data And Forecasts (Morocco 2010-2018)
16
Healthcare Market Forecast
16
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Morocco 2010-2018)
17
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Morocco 2010-2018)
18
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Morocco 2010-2018)
18
Prescription Drug Market Forecast
19
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Morocco 2010-2018)
20
Patented Drug Market Forecast
20
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Morocco 2010-2018)
21
Generic Drug Market Forecast
22
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Morocco 2010-2018)
24
OTC Medicine Market Forecast
24
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Morocco 2010-2018)
25
Pharmaceutical Trade Forecast
26
Table: Pharmaceutical Trade Data And Forecasts (Morocco 2012-2018)
28
Table: Pharmaceutical Trade Data And Forecasts local currency (Morocco 2012-2018)
28
Other Healthcare Data
29
Key Risks To BMI's Forecast Scenario
30
Macroeconomic Forecasts
31
Economic Analysis
31
Table: MOROCCO - GDP BY EXPENDITURE, REAL GROWTH %
37
Industry Risk Reward Ratings
38
Middle East & Africa Risk/Reward Ratings
38
Morocco Risk/ Reward Ratings
46
Rewards
46
Risks
47
Market Overview
49
Industry Trends And Developments
50
Epidemiology
50
Healthcare Sector
53
Healthcare Insurance
56
Recent Health Insurance Developments
59
Research & Development
62
Clinical Trials
63
Regulatory Development
64
Intellectual Property Regime
65
Pricing Regime
65
Reimbursement Regime
67
Competitive Landscape
70
Pharmaceutical Industry
70
Table: Morocco's Select Pharmaceutical Industry Indicators
70
Table: Members Of MIS, 2011
71
Table: Members Of AMIP, 2011
72
Domestic Pharmaceutical sector
72
Foreign Pharmaceutical Companies
73
Pharmaceutical Wholesale
75
Pharmaceutical Retail
76
Company Profile
78
Sothema
78
Laprophan
81
Promopharm
84
Sanofi
86
Pfizer
90
GlaxoSmithKline
93
Ranbaxy
95
Demographic Forecast
97
Table: Morocco's Population By Age Group, 1990-2020 ('000)
98
Table: Morocco's Population By Age Group, 1990-2020 (% of total)
99
Table: Morocco's Key Population Ratios, 1990-2020
100
Table: Morocco's Rural And Urban Population, 1990-2020
100
Glossary
101
Methodology
103
Pharmaceutical Expenditure Forecast Model
103
Healthcare Expenditure Forecast Model
103
Notes On Methodology
104
Risk/Reward Ratings Methodology
105
Ratings Overview
106
Table: Pharmaceutical Risk/Reward Ratings Indicators
106
Indicator Weightings
107

The Morocco Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Morocco Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Moroccan pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Morocco to test other views - a key input for successful budgeting and strategic business planning in the Moroccan pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Moroccan pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Morocco.
  • Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.

Coverage

BMI Industry View & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.

Market Summary

Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

BMI Industry Forecasts

Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)

Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)

Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)

Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)

OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)

Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)

Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Company Profiles

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc